Exp Clin Endocrinol Diabetes 2018; 126(06): 394-400
DOI: 10.1055/s-0043-120760
Article
© Georg Thieme Verlag KG Stuttgart · New York

Impact of type 2 Diabetes and Metformin use on Vitamin B12 Associated Biomarkers - an Observational Study

Corina Metaxas
1   Pharmaceutical Care Research Group, University of Basel, Switzerland
,
Chantal Zurwerra
1   Pharmaceutical Care Research Group, University of Basel, Switzerland
,
Gottfried Rudofsky
2   Department of Medicine, Kantonsspital Olten, Switzerland
,
Kurt E. Hersberger
1   Pharmaceutical Care Research Group, University of Basel, Switzerland
,
Philipp N. Walter
1   Pharmaceutical Care Research Group, University of Basel, Switzerland
3   Institute of Laboratory Medicine, Solothurn Hospitals, Switzerland
› Author Affiliations
Further Information

Publication History

received 07 August 2017
revised 29 September 2017

accepted 05 October 2017

Publication Date:
02 February 2018 (online)

Abstract

Aims Assessment of the impact of type 2 diabetes (T2DM) and metformin use on vitamin B12 (VB12) associated biomarkers and their suitability to represent VB12 supply.

Methods Differences of VB12, holotranscobalamine (HoloTc), the biologically active fraction  (%AB12)=HoloTc/VB12*100 and homocystein (Hcy) were analysed i) among diabetic outpatients with (DMMet+ ) and without metformin use (DMMet-) and ii) in comparison to an external non-diabetic reference group with low VB12 (<200 pmol/L).

Results VB12 associated biomarkers were distributed equally between DMMet+  (n=29, 58%) and DMMet- (n=21, 42%). Significant differences in %AB12 in diabetic patients with low VB12 (n=19) compared to the non-diabetic reference group (n=31) were found. Higher %AB12 was associated with diabetes. Hcy levels were significantly associated with age, folic acid level, renal function and HoloTc but not with VB12.

Conclusions In T2DM patients with low VB12, %AB12 was confirmed as being higher in comparison to nondiabetic patients. The effect was not clearly attributable to metformin use. HoloTc was unaffected by the lowering of VB12 and significantly associated with the functional marker Hcy. Both findings support the use of HoloTc for the assessment of VB12 supply in diabetic patients.